Navigation Links
For Aggressive Breast Cancer, Chemo May Work Better in the Young
Date:12/6/2012

By Mary Brophy Marcus
HealthDay Reporter

THURSDAY, Dec. 6 (HealthDay News) -- Younger women with aggressive breast cancers often benefit more than older women when they undergo early, pre-operative chemotherapy, a new study finds.

A team of German scientists found that women aged 35 or younger who underwent "neoadjuvant" chemotherapy -- chemo given before surgery to help shrink a tumor and make it more operable -- responded better than women over 35 who received the same treatment.

"This study suggests that chemotherapy is a good idea early on in younger patients. In our study, the younger-than-35 women had a higher chance of having no residual tumor left in the breast than older women," said study author Dr. Sibylle Loibl, associate professor of obstetrics and gynecology at the University of Frankfurt, in Germany.

The research is to be presented Thursday at the 2012 San Antonio Breast Cancer Symposium in San Antonio, Texas.

"Breast cancer in young women is rare -- only about 5 percent of patients are under 35," Loibl noted. Tumors in younger women, however, tend to be more aggressive, so researchers are keen to find successful treatments for this age group.

To help do so, Loibl and colleagues evaluated the health records of almost 9,000 women with operable or locally advanced breast cancers that had not yet spread beyond the breast. All of the women were treated with neoadjuvant chemotherapy, which could include radiation, drugs or both. The data was drawn from eight German studies.

A smaller subgroup of more than 700 women aged 35 and younger was compared to the older women with the disease. Loibl said the researchers looked at patient survival rates as well as "pathologic complete response," meaning the absence of any residual invasive cancer in the breast. They also looked at the absence or presence of metastatic cells in the lymph nodes near the breasts.

The response to neoadjuvant chemotherapy treatment was significantly higher in the younger women -- nearly 24 percent of the younger women responded to the treatment compared with about 16 percent of the older patients, Loibl said.

The biological makeup of a young woman's tumor also seemed to play a role, she added. Breast cancer specialists divide tumors into separate molecular subtypes based on cellular receptors and other key factors. Loibl said young women with what are called "luminal" tumors seemed to do especially well after neoadjuvant chemotherapy.

"This is not true for other age groups, which indicates that breast cancer in the young -- even when it is a luminal-type breast cancer -- is chemosensitive," she said in a symposium press release.

One expert said the findings are in line with current thinking on breast cancer.

"We've learned that breast cancer is certainly not one disease but a family of diseases, and it presents differently in different women," said Chandini Portteus, vice president of research, evaluation and scientific programs at the nonprofit advocacy group Susan G. Komen for the Cure.

"This study offers more understanding that a younger age group has a different type of breast cancer and a different response to treatment," said Portteus, who is attending the conference in San Antonio. "These women specifically have a luminal-type breast cancer and triple negative breast cancer, and we know those are more aggressive subtypes of cancer that present earlier on in life than some others, but we don't yet know enough about how to predict who will be at risk."

Dr. Patricia Ganz, director of the division of cancer prevention and control research at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, said, "What this tells us is that in spite of having a higher-risk disease, younger women paradoxically have a better likelihood of response due to the types of breast cancer they are more likely to have."

Ganz, who also is attending the conference, said the study is unique because of the large sample of breast cancer patients under age 35 that the researchers were able to analyze statistically.

"They were able to combine eight trials with over 6,500 women whose tumors were able to be evaluated," she said. "Breast cancer in women this age is so uncommon that a single trial would not be able to answer this question."

Should the findings change treatment protocol in women under 35?

The researchers did not compare neoadjuvant chemotherapy to other treatments, but study author Loibl said chemotherapy early "may be a good idea" in younger patients.

For her part, Ganz said the findings do not change treatment recommendations, but they do help explain the differences in disease characteristics in younger women and show that they actually may benefit from chemotherapy.

"The decision to use neoadjuvant therapy is based on the size of the tumor and the woman's desire for possible breast conservation," Ganz said. "Studies have not shown any survival benefit by giving the same chemotherapy before, instead of after, breast surgery."

Research presented at medical meetings should be considered preliminary because it hasn't undergone a peer-review process.

More information

Learn more about breast cancer care at the American Cancer Society.

SOURCES: Sibylle Loibl, M.D., Ph.D., associate professor, obstetrics and gynecology, University of Frankfurt, Germany; Chandini Portteus, vice president of research, evaluation and scientific programs, Susan G. Komen for the Cure; Patricia Ganz, M.D., professor, health services, School of Public Health and professor, medicine, David Geffen School of Medicine, University of California, Los Angeles, and director, division of cancer prevention and control research, Jonsson Comprehensive Cancer Center, Los Angeles; presentation, Dec. 6, 2012, San Antonio Breast Cancer Symposium


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Later End-of-Life Discussions May Mean More Aggressive Treatment
2. Study demonstrates that earlier end of life care discussions are linked to less aggressive care in final days of life
3. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
4. Routine blood test predicts prognosis in aggressive skin cancer
5. Scientists decode software instructions of aggressive leukemia cells
6. Minorities most likely to have aggressive tumors, less likely to get radiation
7. Least Aggressive Breast Cancer Still Poses Long-Term Risk, Study Finds
8. Study finds least aggressive form of breast cancer still poses risk for death years later
9. Lack of sleep found to be a new risk factor for aggressive breast cancers
10. Gene Might Predict Brain Tumors Aggressiveness
11. The making and unmaking of stem-like, aggressive breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
For Aggressive Breast Cancer, Chemo May Work Better in the Young
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: